# Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

> **NCT04207255** · PHASE2 · COMPLETED · sponsor: **Medical University of South Carolina** · enrollment: 69 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Opaganib
- **DRUG:** Abiraterone
- **DRUG:** Enzalutamide
- **DRUG:** Opaganib

## Key facts

- **NCT ID:** NCT04207255
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-27
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04207255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04207255, "Addition of Opaganib to Androgen Antagonists in Patients With mCRPC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04207255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*